CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹987 Cr | ₹936 Cr | ₹634 Cr | ₹567 Cr | ₹743 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹987 Cr |
| Mar2025 | ₹936 Cr |
| Mar2024 | ₹634 Cr |
| Mar2023 | ₹567 Cr |
| Mar2022 | ₹743 Cr |
How is Contingent Liabilities of CIPLA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹987 Cr | 5.48 | |
| Mar2025 | ₹936 Cr | 47.65 | |
| Mar2024 | ₹634 Cr | 11.90 | |
| Mar2023 | ₹567 Cr | -23.73 | |
| Mar2022 | ₹743 Cr | - | |
Compare Contingent Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹106,065.2 Cr | 0.6% | -3.8% | -11% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,620.0 Cr | -0.2% | -5.1% | 8.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,714.0 Cr | -3.8% | -3.2% | 51.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹174,741.0 Cr | -1.7% | -7.7% | 29.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,339.0 Cr | 2.9% | 4.6% | 0.4% | Stock Analytics | |
| MANKIND PHARMA | ₹96,243.6 Cr | -2.9% | 2.3% | -3.3% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 0.6% |
-3.8% |
-11% |
| SENSEX | 0.2% |
-2.8% |
-11.2% |
You may also like the below Video Courses